IRM
41
3
TDC
86
2
MKC
63
-2
DLTR
51
-3
CAH
41
-6
FLS
73
4
EXC
51
-2
M
50
-3
PPL
44
-3
UAL
76
3
ALL
37
-3
EQIX
63
3
PAYX
47
-3
AZO
58
-2
CCL
72
2
PRU
47
-4
XOM
37
-2
HSY
38
-7
APA
37
2
C
60
-2
IRM
41
3
TDC
86
2
MKC
63
-2
DLTR
51
-3
CAH
41
-6
FLS
73
4
EXC
51
-2
M
50
-3
PPL
44
-3
UAL
76
3
ALL
37
-3
EQIX
63
3
PAYX
47
-3
AZO
58
-2
CCL
72
2
PRU
47
-4
XOM
37
-2
HSY
38
-7
APA
37
2
C
60
-2
Financhill
Back

Pliant Therapeutics 10K Form

Buy
68

PLRX
Pliant Therapeutics

Last Price:
13.88
Seasonality Move:
13.39%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLRX News And Ratings

See the #1 stock for the next 7 days that we like better than PLRX

PLRX Financial Statistics

Sales & Book Value

Annual Sales: $1.58M
Cash Flow: $-33.17M
Price / Cash Flow: 0
Annual Sales: $5.68
Price / Book: 2.5

Profitability

EPS (TTM): -3.34000
Net Income (TTM): $-201.68M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Pliant Therapeutics Earnings Forecast

Key Pliant Therapeutics Financial Ratios

  • The Research & Development expenses have been 8,088.42% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of PLRX is -10,211.14% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Pliant Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PLRX
CUSIP: 729139
Website: pliantrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PLRX Technical Analysis vs Fundamental Analysis

Buy
68
Pliant Therapeutics (PLRX) is a Buy

Is Pliant Therapeutics a Buy or a Sell?